Valuation: Atara Biotherapeutics, Inc.

Market Cap 81.31M 72.91M 67.2M 61.03M 115M 7.62B 119M 805M 321M 4.08B 305M 299M 12.91B P/E 2026 *
-8.18x
P/E 2027 * 6.83x
Enterprise Value 81.31M 72.91M 67.2M 61.03M 115M 7.62B 119M 805M 321M 4.08B 305M 299M 12.91B EV / Sales 2026 *
28.5x
EV / Sales 2027 * 1.99x
Free-Float
83.2%
Yield 2026 *
-
Yield 2027 * -
1 day-0.98%
1 week-1.22%
Current month+1.12%
1 month-14.56%
3 months-5.92%
6 months-2.88%
Current year-55.22%
1 week 7.47
Extreme 7.47
8.38
1 month 7.47
Extreme 7.47
9.99
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
39.5
5 years 3.92
Extreme 3.92
471.25
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-08
Director of Finance/CFO 61 2026-06-25
Investor Relations Contact - 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-02-28
Director/Board Member 66 2015-11-22
Director/Board Member 53 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Buy

Director

104,166 1.0377%
8/17/26 Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-1.22%-34.15%+40.99% 82.11M
+0.01%+11.10%+60.83%+70.43% 68.22B
+1.22%+9.56%+15.97%+90.23% 59.82B
+0.24%+1.35%+23.78%+97.55% 56.07B
+1.60%+19.44%+28.80%+112.95% 47.67B
-1.32%+4.78%+29.15%+40.40% 45.95B
-3.54%-0.60%+207.76%+879.50% 43.29B
-3.33%+6.90%+22.78%+48.07% 35.66B
-2.19%-3.71%+90.94%+66.33% 34.73B
+2.92%+14.41%-37.74%+403.12% 25.47B
Average -0.54%+4.52%+40.81%+184.96% 42B
Weighted average by Cap. -0.41%+5.50%+50.73%+180.53%

Financials

2026 *2027 *
Net sales 2.85M 2.55M 2.35M 2.14M 4.05M 267M 4.16M 28.19M 11.23M 143M 10.69M 10.46M 452M 40.87M 36.65M 33.78M 30.67M 58.05M 3.83B 59.67M 404M 161M 2.05B 153M 150M 6.49B
Net income -14.62M -13.11M -12.08M -10.97M -20.77M -1.37B -21.35M -145M -57.65M -734M -54.87M -53.7M -2.32B 18.66M 16.73M 15.42M 14M 26.5M 1.75B 27.24M 185M 73.56M 937M 70.01M 68.53M 2.96B
Net Debt - -
Projected Income Statement - Annual - Atara Biotherapeutics, Inc.
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
26-11-10 US$8.100 -0.98% 33,144
26-11-09 US$8.180 +3.94% 13,696
26-11-06 US$7.870 -1.13% 16,300
26-11-05 US$7.960 -4.90% 29,548
26-11-04 US$8.370 +2.07% 9,481
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Atara Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.100USD
Average target price
13.67USD
Spread / Average Target
+68.72%
  1. Stock Market
  2. Stocks
  3. ATRA Stock